Massachusetts Medicaid Wants to Stop Covering “High Cost” Drugs Bought Through 340B
(Editor’s note: The Medicare Payment Advisory Commission (MedPAC) tomorrow will consider a staff analysis of “whether the availability of 340B drug discounts creates incentives to choose more expensive products in some cases and the resulting impact on Medicare patients’ cost-share ...